Novo Nordisk Annual Report 2021
Financial statements of the parent company
8 Financial assets
Invest-
ments in
Amounts
owed by
subsi-
affiliated
Invest-
ment in
associated
Other
securities
and invest-
DKK million
diaries companies
company
ments
2021
2020
Cost at the beginning of the year
29,174
4,047
105
1,220
34,546
18,493
Investments during the year
19,698
1,255
67
21,020
29,629
Divestments and repayments during the year
(989)
(590)
(1,579)
(13,576)
Cost at the end of the year
48,872
4,313
105
697
53,987
34,546
Value adjustments at the beginning of the year
26,255
(245)
111
(452)
25,669
28,803
Profit/(loss) before tax
19,635
19,635
18,187
Share of result after tax in associated company
(13)
(13)
21
Income taxes on profit for the year
(2,006)
(2,006)
(3,748)
Market value adjustment
Dividends received
75
75
(171)
(11,050)
(4)
(11,054)
(16,785)
Divestments during the year
216
216
(3)
Effect of exchange rate adjustment charged to the income statement
281
17
298
Effect of exchange rate adjustment charged to equity
2,603
10
2,613
(3,103)
Other adjustments
500
500
2,468
Value adjustments at the end of the year
35,937
46
46
94
(144)
35,933
Unrealised internal profit at the beginning of the year
(16,617)
Unrealised internal profit movements in the year
(750)
(16,617)
(750)
25,669
(13,420)
(4,045)
Effect of exchange rate adjustment charged to equity
(989)
(989)
848
Unrealised internal profit at the end of the year
Carrying amount at the end of the year
(18,356)
66,453
4,359
199
553
(18,356)
71,564
(16,617)
43,598
Novo Nordisk Annual Report 2021 102
The carrying amount of investments in subsidiaries does not include
capitalised goodwill at the end of the year. For a list of companies in the
Novo Nordisk Group, please refer to note 5.7 to the consolidated financial
statements.View entire presentation